In July 2016, Vermont’s Act 120 will take effect, requiring food manufacturers that sell into the state to indicate on food labels whether their products are made using genetic engineering.
The DEA has been active lately. A couple of weeks ago, it announced it would make a decision soon regarding rescheduling marijuana. On April 22, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced the DEA had finally approved its application for the first approved study of smoked marijuana for effectiveness in treating PTSD.
As the 23 June date for the British referendum about its future in the European Union (EU) comes closer, the EU political leadership in Brussels remains uncertain how best to support the ‘Bremain’ forces in order to avoid the embarrassing and damaging departure of one of its largest and strongest members.
Earlier this month, I attended a conference at the University of Michigan Law School: Autonomous Vehicles: Legal and Regulatory Hurdles to Deployment.
“Evidence-based medical treatment guidelines” sounds like such a good idea. Who would want medical treatment that wasn’t based on evidence?
IPO activity so far this year is well off the pace compared to this time a year ago.
Monday Morning Regulatory Review – 4/25/16: Medicare Reimbursements; Medical Facility Fire Safety; And More
This week’s highlights in regulatory practice seem to focus on periodic regulations from the Department of Health and Human Services (HHS) Centers for Medicare and Medicaid Services (CMS).
One of the more successful strategies when defending against class actions is to force the plaintiff out of court and into arbitration.
This is going to be a big year for cannabis.
Because this blog is more than ten years old, there is hardly a China business or law situation of which we have not written at least once.